Vivian A Fonseca

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4014850/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. Endocrine Practice, 2017, 23, 1-87.	2.1	766
2	Metabolic Effects of Carvedilol vs Metoprolol in Patients With Type 2 Diabetes Mellitus and Hypertension. JAMA - Journal of the American Medical Association, 2004, 292, 2227.	7.4	710
3	Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus. Diabetes Care, 2007, 30, 162-172.	8.6	577
4	Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure. Diabetes Care, 2004, 27, 256-263.	8.6	561
5	Effect of Metformin and Rosiglitazone Combination Therapy in Patients With Type 2 Diabetes Mellitus. JAMA - Journal of the American Medical Association, 2000, 283, 1695.	7.4	476
6	Effects of Cardiac Autonomic Dysfunction on Mortality Risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Diabetes Care, 2010, 33, 1578-1584.	8.6	435
7	Defining and Characterizing the Progression of Type 2 Diabetes. Diabetes Care, 2009, 32, S151-S156.	8.6	416
8	Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm – 2016 EXECUTIVE SUMMARY. Endocrine Practice, 2016, 22, 84-113.	2.1	405
9	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary. Endocrine Practice, 2018, 24, 91-121.	2.1	388
10	Hypoglycemia, Diabetes, and Cardiovascular Events. Diabetes Care, 2010, 33, 1389-1394.	8.6	374
11	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive type 2 Diabetes Management Algorithm – 2017 Executive Summary. Endocrine Practice, 2017, 23, 207-238.	2.1	362
12	Nonhypoglycemic Effects of Thiazolidinediones. Annals of Internal Medicine, 2001, 134, 61.	3.9	359
13	The Effects of Salsalate on Glycemic Control in Patients With Type 2 Diabetes. Annals of Internal Medicine, 2010, 152, 346.	3.9	343
14	Association of Hypoglycemia and Cardiac Ischemia: A study based on continuous monitoring. Diabetes Care, 2003, 26, 1485-1489.	8.6	341
15	Systematic Review: Glucose Control and Cardiovascular Disease in Type 2 Diabetes. Annals of Internal Medicine, 2009, 151, 394.	3.9	308
16	Bile Acids and Metabolic Regulation. Diabetes Care, 2009, 32, S237-S245.	8.6	304
17	The 11-Î ² -Hydroxysteroid Dehydrogenase Type 1 Inhibitor INCB13739 Improves Hyperglycemia in Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy. Diabetes Care, 2010, 33, 1516-1522.	8.6	281
18	Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implications. Kidney International, 2009, 75, 1272-1277.	5.2	280

#	Article	IF	CITATIONS
19	Effect of thiazolidinediones on body weight in patients with diabetes mellitus. American Journal of Medicine, 2003, 115, 42-48.	1.5	262
20	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2019 Executive Summary. Endocrine Practice, 2019, 25, 69-101.	2.1	245
21	Oxidants in Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2007, 18, 16-28.	6.1	242
22	Colesevelam HCl Improves Glycemic Control and Reduces LDL Cholesterol in Patients With Inadequately Controlled Type 2 Diabetes on Sulfonylurea-Based Therapy. Diabetes Care, 2008, 31, 1479-1484.	8.6	242
23	Acute and Prolonged Effects of Sildenafil on Brachial Artery Flow-Mediated Dilatation in Type 2 Diabetes. Diabetes Care, 2002, 25, 1336-1339.	8.6	238
24	Salicylate (Salsalate) in Patients With Type 2 Diabetes. Annals of Internal Medicine, 2013, 159, 1.	3.9	219
25	Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy. Diabetes Care, 2012, 35, 1225-1231.	8.6	209
26	Menopausal Hormone Therapy and Type 2 Diabetes Prevention: Evidence, Mechanisms, and Clinical Implications. Endocrine Reviews, 2017, 38, 173-188.	20.1	206
27	Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro. Diabetes Care, 2014, 37, 2317-2325.	8.6	186
28	Efficacy and Safety of Colesevelam in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Receiving Insulin-Based Therapy. Archives of Internal Medicine, 2008, 168, 1531.	3.8	184
29	Impact of a Natural Disaster on Diabetes. Diabetes Care, 2009, 32, 1632-1638.	8.6	146
30	Hyperhomocysteinemia following a methionine load in patients with non-insulin-dependent diabetes mellitus and macrovascular disease. Metabolism: Clinical and Experimental, 1996, 45, 133-135.	3.4	138
31	Type 2 Diabetes and Hypertension. Circulation Research, 2019, 124, 930-937.	4.5	136
32	Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Annals of Epidemiology, 2004, 14, 686-695.	1.9	131
33	Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes, Obesity and Metabolism, 2010, 12, 384-392.	4.4	124
34	Effects of β-blockers on glucose and lipid metabolism. Current Medical Research and Opinion, 2010, 26, 615-629.	1.9	122
35	Effect of Troglitazone on Fibrinolysis and Activated Coagulation in Patients With Non–Insulin-Dependent Diabetes Mellitus. Journal of Diabetes and Its Complications, 1998, 12, 181-186. 	2.3	115
36	Plasma homocysteine concentrations are regulated by acute hyperinsulinemia in nondiabetic but not type 2 diabetic subjects. Metabolism: Clinical and Experimental, 1998, 47, 686-689.	3.4	114

#	Article	IF	CITATIONS
37	Diabetic nephropathy and retinopathy. Medical Clinics of North America, 2004, 88, 1001-1036.	2.5	111
38	Drugs Affecting Homocysteine Metabolism. Drugs, 2002, 62, 605-616.	10.9	108
39	Hyperhomocysteinemia and the Endocrine System: Implications for Atherosclerosis and Thrombosis. Endocrine Reviews, 1999, 20, 738-759.	20.1	102
40	Therapeutic Approaches to Target Inflammation in Type 2 Diabetes. Clinical Chemistry, 2011, 57, 162-167.	3.2	102
41	Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet, The, 2012, 379, 2262-2269.	13.7	100
42	Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus. BMJ Open, 2019, 9, e024954.	1.9	100
43	Body Weight Changes with β-Blocker Use: Results from GEMINI. American Journal of Medicine, 2007, 120, 610-615.	1.5	95
44	Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus. American Journal of Nephrology, 2019, 49, 331-342.	3.1	95
45	Hospital Discharge Algorithm Based on Admission HbA1c for the Management of Patients With Type 2 Diabetes. Diabetes Care, 2014, 37, 2934-2939.	8.6	94
46	Impact of Hypoglycemia Associated With Antihyperglycemic Medications on Vascular Risks in Veterans With Type 2 Diabetes. Diabetes Care, 2012, 35, 1126-1132.	8.6	93
47	Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes mellitus. Current Medical Research and Opinion, 2003, 19, 635-631.	1.9	90
48	Metanx in Type 2 Diabetes with Peripheral Neuropathy: A Randomized Trial. American Journal of Medicine, 2013, 126, 141-149.	1.5	88
49	Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease. Circulation, 2018, 138, 2908-2918.	1.6	88
50	Association of Urinary Biomarkers of Inflammation, Injury, and Fibrosis with Renal Function Decline: The ACCORD Trial. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1343-1352.	4.5	85
51	Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm. American Journal of Medicine, 2005, 118, 939-947.	1.5	83
52	Endothelial and Erectile Dysfunction, Diabetes Mellitus, and the Metabolic Syndrome: Common Pathways and Treatments?. American Journal of Cardiology, 2005, 96, 13-18.	1.6	82
53	Effects of a high-fat—sucrose diet on enzymes in homocysteine metabolism in the rat. Metabolism: Clinical and Experimental, 2000, 49, 736-741.	3.4	81
54	Surge in Newly Identified Diabetes Among Medicaid Patients in 2014 Within Medicaid Expansion States Under the Affordable Care Act. Diabetes Care, 2015, 38, 833-837.	8.6	80

#	Article	IF	CITATIONS
55	Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy. Diabetes Care, 2010, 33, 730-732.	8.6	76
56	Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. Journal of Diabetes and Its Complications, 2013, 27, 268-273.	2.3	76
57	Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials. Journal of Diabetes and Its Complications, 2014, 28, 399-405.	2.3	75
58	From guideline to patient: a review of recent recommendations for pharmacotherapy of painful diabetic neuropathy. Journal of Diabetes and Its Complications, 2015, 29, 146-156.	2.3	75
59	Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial. Diabetes Care, 2016, 39, 1579-1586.	8.6	72
60	Association between Inflammation and Biological Variation in Hemoglobin A1c in U.S. Nondiabetic Adults. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2364-2371.	3.6	70
61	Bile Acid Sequestrants for Lipid and Glucose Control. Current Diabetes Reports, 2010, 10, 70-77.	4.2	68
62	The metabolic syndrome, hyperlipidemia, and insulin resistance. Clinical Cornerstone, 2005, 7, 61-72.	0.7	65
63	Baseline Vitamin D Status, Sleep Patterns, and the Risk of Incident Type 2 Diabetes in Data From the UK Biobank Study. Diabetes Care, 2020, 43, 2776-2784.	8.6	64
64	Weight Loss in Underserved Patients — A Cluster-Randomized Trial. New England Journal of Medicine, 2020, 383, 909-918.	27.0	62
65	Racial Disparity of Eye Examinations Among the U.S. Working-Age Population With Diabetes: 2002–2009. Diabetes Care, 2014, 37, 1321-1328.	8.6	61
66	Novel Risk Engine for Diabetes Progression and Mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO). Pharmacoeconomics, 2018, 36, 1125-1134.	3.3	61
67	GLP-1 Receptor in Pancreatic α-Cells Regulates Glucagon Secretion in a Glucose-Dependent Bidirectional Manner. Diabetes, 2019, 68, 34-44.	0.6	61
68	A Comparison of Bedtime Insulin Glargine with Bedtime Neutral Protamine Hagedorn Insulin in Patients with Type 2 Diabetes: Subgroup Analysis of Patients Taking Once-Daily Insulin in a Multicenter, Randomized, Parallel Group Study. American Journal of the Medical Sciences, 2004, 328, 274-280.	1.1	57
69	Overview of metformin: special focus on metformin extended release. Expert Opinion on Pharmacotherapy, 2012, 13, 1797-1805.	1.8	52
70	Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes. Journal of Diabetes and Its Complications, 2013, 27, 177-183.	2.3	48
71	Determinants of Weight Gain in the Action to Control Cardiovascular Risk in Diabetes Trial. Diabetes Care, 2013, 36, 2162-2168.	8.6	46
72	Inflammation and emerging risk factors in diabetes mellitus and atherosclerosis. Current Diabetes Reports, 2003, 3, 248-254.	4.2	45

#	Article	IF	CITATIONS
73	Benefits of timely basal insulin control in patients with type 2 diabetes. Journal of Diabetes and Its Complications, 2015, 29, 295-301.	2.3	43
74	PAX4 Gene Transfer Induces α-to-β Cell Phenotypic Conversion and Confers Therapeutic Benefits for Diabetes Treatment. Molecular Therapy, 2016, 24, 251-260.	8.2	42
75	Rosiglitazone reduces serum homocysteine levels, smooth muscle proliferation, and intimal hyperplasia in Sprague-Dawley rats fed a high methionine diet. Metabolism: Clinical and Experimental, 2005, 54, 645-652.	3.4	41
76	Comparison of Glucose Lowering Effect of Metformin and Acarbose in Type 2 Diabetes Mellitus: A Meta-Analysis. PLoS ONE, 2015, 10, e0126704.	2.5	40
77	Therapeutic targets to reduce cardiovascular disease in type 2 diabetes. Nature Reviews Drug Discovery, 2009, 8, 361-367.	46.4	39
78	Differential Effects of Peroxisome Proliferator Activator Receptor-α and γ Ligands on Intimal Hyperplasia After Balloon Catheter-Induced Vascular Injury in Zucker Rats. Journal of Cardiovascular Pharmacology and Therapeutics, 2003, 8, 297-305.	2.0	38
79	The effect of troglitazone on plasma homocysteine, hepatic and red blood cell S-adenosyl methionine, and S-adenosyl homocysteine and enzymes in homocysteine metabolism in Zucker rats. Metabolism: Clinical and Experimental, 2002, 51, 783-786.	3.4	37
80	Addition of Nateglinide to Rosiglitazone Monotherapy Suppresses Mealtime Hyperglycemia and Improves Overall Glycemic Control. Diabetes Care, 2003, 26, 1685-1690.	8.6	37
81	Early identification and treatment of insulin resistance: Impact on subsequent prediabetes and type 2 diabetes. Clinical Cornerstone, 2007, 8, S7-S18.	0.7	37
82	Saxagliptin overview: special focus on safety and adverse effects. Expert Opinion on Drug Safety, 2013, 12, 103-109.	2.4	36
83	The Hurricane Katrina Aftermath and Its Impact on Diabetes Care: Observations from "ground zero": lessons in disaster preparedness of people with diabetes. Diabetes Care, 2006, 29, 158-160.	8.6	36
84	Insulin Resistance Syndrome. Southern Medical Journal, 1999, 92, 2-14.	0.7	35
85	Review Paper � CME. Insulin Resistance, Diabetes, Hypertension, and Renin?Angiotensin System Inhibition: Reducing Risk for Cardiovascular Disease. Journal of Clinical Hypertension, 2006, 8, 713-722.	2.0	35
86	Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial. Journal of Diabetes and Its Complications, 2014, 28, 742-749.	2.3	35
87	Estimating Quality of Life Decrements Due to Diabetes Complications in the United States: The Health Utility Index (HUI) Diabetes Complication Equation. Pharmacoeconomics, 2019, 37, 921-929.	3.3	35
88	Dipeptidyl Peptidase-4 as a New Target of Action for Type 2 Diabetes Mellitus: A Systematic Review. Cardiology Clinics, 2008, 26, 639-648.	2.2	34
89	Iron and Diabetes Revisited. Diabetes Care, 2011, 34, 1676-1677.	8.6	33
90	Identification and Treatment of Prediabetes to Prevent Progression to Type 2 Diabetes. Clinical Cornerstone, 2007, 8, 10-20.	0.7	32

#	Article	IF	CITATIONS
91	Sex Differences in Cardiovascular Risk Profile From Childhood to Midlife Between Individuals Who Did and Did Not Develop Diabetes at Follow-up: The Bogalusa Heart Study. Diabetes Care, 2019, 42, 635-643.	8.6	32
92	Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 465-473.	4.5	32
93	Initial Combination Therapy with Metformin and Colesevelam for Achievement of Glycemic and Lipid Goals Min Early Type 2 Diabetes. Endocrine Practice, 2010, 16, 629-640.	2.1	31
94	Economic burden of hypoglycemia in patients with Type 2 diabetes. Expert Review of Pharmacoeconomics and Outcomes Research, 2012, 12, 47-51.	1.4	31
95	Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial. Diabetes Care, 2021, 44, 164-173.	8.6	31
96	Is weight loss possible in patients treated with thiazolidinediones? Experience with a low-calorie diet. Current Medical Research and Opinion, 2003, 19, 609-613.	1.9	30
97	Mechanisms and therapeutic targets in type 2 diabetes mellitus. Drug Discovery Today Disease Mechanisms, 2004, 1, 151-157.	0.8	30
98	Blockade of sodium-glucose cotransporter 2 suppresses high glucose-induced angiotensinogen augmentation in renal proximal tubular cells. American Journal of Physiology - Renal Physiology, 2020, 318, F67-F75.	2.7	30
99	Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients. Vascular Pharmacology, 2006, 45, 29-35.	2.1	29
100	Diabetes treatments have differential effects on nontraditional cardiovascular risk factors. Journal of Diabetes and Its Complications, 2006, 20, 14-20.	2.3	29
101	Effects of the Thiazolidinediones on Cardiovascular Risk Factors. American Journal of Cardiovascular Drugs, 2002, 2, 149-156.	2.2	28
102	Differential association of birth weight with cardiovascular risk variables in African- Americans and Whites: The Bogalusa heart study. Annals of Epidemiology, 2004, 14, 258-264.	1.9	28
103	New Developments in Diabetes Management: Medications of the 21st Century. Clinical Therapeutics, 2014, 36, 477-484.	2.5	27
104	Glycated Albumin at 4 Weeks Correlates with A1C Levels at 12 Weeks and Reflects Short-Term Glucose Fluctuations. Endocrine Practice, 2015, 21, 1195-1203.	2.1	27
105	Rationale for the Use of Insulin Sensitizers to Prevent Cardiovascular Events in Type 2 Diabetes Mellitus. American Journal of Medicine, 2007, 120, S18-S25.	1.5	26
106	Replacement of Sedentary Behavior by Various Daily-Life Physical Activities and Structured Exercises: Genetic Risk and Incident Type 2 Diabetes. Diabetes Care, 2021, 44, 2403-2410.	8.6	26
107	The Effectiveness of Intensive Glycemic Control for the Prevention of Vascular Complications in Diabetes Mellitus. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2006, 5, 273-286.	1.8	25
108	Reductions in Insulin Resistance are Mediated Primarily via Weight Loss in Subjects With Type 2 Diabetes on Semaglutide. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4078-4086.	3.6	25

#	Article	IF	CITATIONS
109	BMI is Associated with Coronavirus Disease 2019 Intensive Care Unit Admission in African Americans. Obesity, 2020, 28, 1798-1801.	3.0	24
110	Effects of a 2-Year Primary Care Lifestyle Intervention on Cardiometabolic Risk Factors. Circulation, 2021, 143, 1202-1214.	1.6	24
111	Management of Type 2 Diabetes: Oral Agents, Insulin, and Injectables. Journal of the American Dietetic Association, 2008, 108, S29-S33.	1.1	23
112	Results of a Study Comparing Glycated Albumin to Other Glycemic Indices. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 677-687.	3.6	23
113	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Journal of Diabetes and Its Complications, 2022, 36, 108101.	2.3	23
114	Missing the Point: Substituting Exenatide for Nonoptimized Insulin: Going from bad to worse!. Diabetes Care, 2007, 30, 2972-2973.	8.6	22
115	Ongoing Clinical Trials Evaluating the Cardiovascular Safety and Efficacy of Therapeutic Approaches to Diabetes Mellitus. American Journal of Cardiology, 2011, 108, 52B-58B.	1.6	22
116	Beta-blockers have a beneficial effect upon endothelial function and microalbuminuria in African-American subjects with diabetes and hypertension. Journal of Diabetes and Its Complications, 2008, 22, 303-308.	2.3	21
117	Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials. Current Medical Research and Opinion, 2010, 26, 1621-1628.	1.9	21
118	The American Diabetes Association Diabetes Research Perspective. Diabetes Care, 2012, 35, 1380-1387.	8.6	21
119	A Systematic Review of Cost-Effectiveness of Sodium-Glucose Cotransporter Inhibitors for Type 2 Diabetes. Current Diabetes Reports, 2020, 20, 12.	4.2	21
120	Early Menopause and Cardiovascular Disease Risk in Women With or Without Type 2 Diabetes: A Pooled Analysis of 9,374 Postmenopausal Women. Diabetes Care, 2021, 44, 2564-2572.	8.6	21
121	Promoting Successful Weight Loss in Primary Care in Louisiana (PROPEL): Rationale, design and baseline characteristics. Contemporary Clinical Trials, 2018, 67, 1-10.	1.8	20
122	Hyperhomocysteinemia In Type 2 Diabetes Mellitus: Cardiovascular Risk Factors And Effect Of Treatment With Folic Acid And Pyridoxine. Endocrine Practice, 2000, 6, 435-441.	2.1	19
123	The impact of antidiabetic therapies on cardiovascular disease. Current Atherosclerosis Reports, 2005, 7, 50-57.	4.8	19
124	Metabolic Syndrome: Underrated or underdiagnosed?. Diabetes Care, 2005, 28, 1831-1832.	8.6	19
125	Identification and Treatment of Prediabetes to Prevent Progression to Type 2 Diabetes. Clinical Cornerstone, 2008, 9, 51-61.	0.7	19
126	The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial. Journal of Diabetes and Its Complications, 2014, 28, 874-879.	2.3	19

#	Article	IF	CITATIONS
127	Impact of thiazolidinedione safety warnings on medication use patterns and glycemic control among veterans with diabetes mellitus. Journal of Diabetes and Its Complications, 2011, 25, 143-150.	2.3	18
128	Sex Differences in the Progression of Metabolic Risk Factors in Diabetes Development. JAMA Network Open, 2022, 5, e2222070.	5.9	18
129	The PROactive Study—The Glass Is Half Full. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 25-27.	3.6	17
130	Incretin-Based Therapies in Complex Patients: Practical Implications and Opportunities for Maximizing Clinical Outcomes: A Discussion with Dr. Vivian A. Fonseca. American Journal of Medicine, 2011, 124, S54-S61.	1.5	17
131	Update on Safety Issues Related to Antihyperglycemic Therapy. Diabetes Spectrum, 2014, 27, 92-100.	1.0	17
132	Association Between Colchicine and Risk of Diabetes Among the Veterans Affairs Population With Gout. Clinical Therapeutics, 2015, 37, 1206-1215.	2.5	17
133	The role of basal insulin therapy in patients with type 2 diabetes mellitus. Insulin, 2006, 1, 51-60.	0.2	16
134	Time to Recovery in Diabetes and Comorbidities Following Hurricane Katrina. Disaster Medicine and Public Health Preparedness, 2010, 4, S33-S38.	1.3	16
135	Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium–Glucose Transporter 2 Inhibitors. Diabetes Care, 2020, 43, 1530-1536.	8.6	16
136	Economic burden of diabetes-related hypoglycemia on patients, payors, and employers. Journal of Diabetes and Its Complications, 2021, 35, 107916.	2.3	16
137	Economic burden of hypoglycemia: Utilization of emergency department and outpatient services in the United States (2005–2009). Journal of Medical Economics, 2016, 19, 852-857.	2.1	15
138	Biomedical Journals and Preprint Services: Friends or Foes?. Clinical Chemistry, 2017, 63, 453-458.	3.2	15
139	Long-term outcomes associated with triple-goal achievement in patients with type 2 diabetes mellitus (T2DM). Diabetes Research and Clinical Practice, 2018, 140, 45-54.	2.8	15
140	Potential Gains in Life Expectancy Associated With Achieving Treatment Goals in US Adults With Type 2 Diabetes. JAMA Network Open, 2022, 5, e227705.	5.9	15
141	Management of the insulin resistance syndrome. Current Diabetes Reports, 2001, 1, 140-147.	4.2	14
142	Role of insulin secretagogues and insulin sensitizing agents in the prevention of cardiovascular disease in patients who have diabetes. Cardiology Clinics, 2005, 23, 119-138.	2.2	14
143	Cardiovascular events and insulin therapy: A retrospective cohort analysis. Diabetes Research and Clinical Practice, 2008, 81, 97-104.	2.8	14
144	The American Diabetes Association Diabetes Research Perspective. Diabetes, 2012, 61, 1338-1345.	0.6	14

#	Article	IF	CITATIONS
145	Achieving glycaemic targets with basal insulin in T2DM by individualizing treatment. Nature Reviews Endocrinology, 2014, 10, 276-281.	9.6	13
146	Addressing Regional Differences in Diabetes Progression: Global Calibration for Diabetes Simulation Model. Value in Health, 2019, 22, 1402-1409.	0.3	13
147	Potential Role of Metal Chelation to Prevent the Cardiovascular Complications of Diabetes. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2931-2941.	3.6	13
148	Using the RE-AIM framework to evaluate internal and external validity of mobile phone–based interventions in diabetes self-management education and support. Journal of the American Medical Informatics Association: JAMIA, 2020, 27, 946-956.	4.4	13
149	Insulin glargine reduces carotid intimal hyperplasia after balloon catheter injury in Zucker fatty rats possibly by reduction in oxidative stress. Molecular and Cellular Biochemistry, 2009, 330, 1-8.	3.1	12
150	Diabetes control in Asian Americans — Disparities and the role of acculturation. Primary Care Diabetes, 2021, 15, 187-190.	1.8	12
151	Potential Cardiovascular Benefits of Insulin Sensitizers. Endocrinology and Metabolism Clinics of North America, 2005, 34, 117-135.	3.2	11
152	The effects of insulin on the endothelium. Endocrinology and Metabolism Clinics of North America, 2007, 36, 20-26.	3.2	11
153	Safety evaluation of colesevelam therapy to achieve glycemic and lipid goals in type 2 diabetes. Expert Opinion on Drug Safety, 2011, 10, 305-310.	2.4	11
154	Pioglitazone Restores Endothelial Function in Patients with Type 2 Diabetes Treated with Insulin. Metabolic Syndrome and Related Disorders, 2006, 4, 179-184.	1.3	10
155	Differential Effects of Linagliptin on the Function of Human Islets Isolated from Non-diabetic and Diabetic Donors. Scientific Reports, 2017, 7, 7964.	3.3	10
156	Chelation therapy to prevent diabetes-associated cardiovascular events. Current Opinion in Endocrinology, Diabetes and Obesity, 2018, 25, 258-266.	2.3	10
157	Impact of Simultaneous Versus Sequential Initiation of Basal Insulin and Glucagon-like Peptide-1 Receptor Agonists on HbA1c in Type 2 Diabetes: A Retrospective Observational Study. Diabetes Therapy, 2020, 11, 995-1005.	2.5	10
158	Fatty liver index and left ventricular mass: prospective associations from two independent cohorts. Journal of Hypertension, 2021, 39, 961-969.	0.5	10
159	Sex differences in soluble prorenin receptor in patients with type 2 diabetes. Biology of Sex Differences, 2021, 12, 33.	4.1	10
160	Impact of Quality Improvement (QI) Program on 5-Year Risk of Diabetes-Related Complications: A Simulation Study. Diabetes Care, 2020, 43, 2847-2852.	8.6	9
161	Revisiting The Use of Pioglitazone in the Treatment of Type 2 Diabetes. Endocrine Practice, 2016, 22, 1343-1346.	2.1	8
162	Diabetes medication regimens and patient clinical characteristics in the national patientâ€centered clinical research network, PCORnet. Pharmacology Research and Perspectives, 2020, 8, e00637.	2.4	8

#	Article	IF	CITATIONS
163	Urinary Catalytic Iron in Obesity. Clinical Chemistry, 2011, 57, 272-278.	3.2	7
164	Will the Affordable Care Act (ACA) Improve Racial/Ethnic Disparity of Eye Examination Among US Working-Age Population with Diabetes?. Current Diabetes Reports, 2016, 16, 58.	4.2	7
165	Utility of existing diabetes risk prediction tools for young black and white adults: Evidence from the Bogalusa Heart Study. Journal of Diabetes and Its Complications, 2017, 31, 86-93.	2.3	7
166	Differential sex effects of systolic blood pressure and lowâ€density lipoprotein cholesterol on type 2 diabetes: Life course data from the Bogalusa Heart Study. Journal of Diabetes, 2018, 10, 449-457.	1.8	7
167	When should fixed ratio basal insulin/glucagon-like peptide-1 receptor agonists combination products be considered?. Journal of Diabetes and Its Complications, 2019, 33, 107473.	2.3	7
168	Diabetes INSIDE: Improving Population HbA1c Testing and Targets in Primary Care With a Quality Initiative. Diabetes Care, 2020, 43, 329-336.	8.6	7
169	Glycated hemoglobin A1c(HbA1c) and diabetes: a new era?. Current Medical Research and Opinion, 2011, 27, 7-11.	1.9	6
170	Variabilities in Childhood Cardiovascular Risk Factors and Incident Diabetes in Adulthood: The Bogalusa Heart Study. Diabetes Care, 2019, 42, 1816-1823.	8.6	6
171	Pax4 Gene Delivery Improves Islet Transplantation Efficacy by Promoting β Cell Survival and α-to-β Cell Transdifferentiation. Cell Transplantation, 2020, 29, 096368972095865.	2.5	6
172	Realâ€world evidence of the effectiveness on glycaemic control of early simultaneous versus later sequential initiation of basal insulin and glucagonâ€like peptideâ€1 receptor agonists. Diabetes, Obesity and Metabolism, 2020, 22, 2295-2304.	4.4	6
173	Patient-specific factors associated with use of diabetes self-management education and support programs in Louisiana. BMJ Open Diabetes Research and Care, 2021, 9, e002136.	2.8	6
174	Predicting incident heart failure among patients with type 2 diabetes mellitus: The <scp>DM URE</scp> risk score. Diabetes, Obesity and Metabolism, 2022, 24, 2203-2211.	4.4	6
175	The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial and Hurricane Katrina: Lessons for managing clinical trials during and after a natural disaster. Contemporary Clinical Trials, 2008, 29, 756-761.	1.8	5
176	Urinary Catalytic Iron in Patients with Type 2 Diabetes without Microalbuminuria—a Substudy of the ACCORD Trial. Clinical Chemistry, 2011, 57, 341-344.	3.2	5
177	Glucose Control and Cardiovascular Outcomes in Individuals with Diabetes Mellitus. Heart Failure Clinics, 2012, 8, 513-522.	2.1	5
178	Diabetes Mellitus in the Next Decade: Novel Pipeline Medications to Treat Hyperglycemia. Clinical Therapeutics, 2013, 35, 714-723.	2.5	5
179	Triple combination of insulin glargine, sitagliptin and metformin in type 2 diabetes: The EASIE post-hoc analysis and extension trial. Journal of Diabetes and Its Complications, 2015, 29, 134-141.	2.3	5
180	Prevalence of Metabolic Acidosis Among Patients with Chronic Kidney Disease and Hyperkalemia. Advances in Therapy, 2021, 38, 5238-5252.	2.9	5

#	Article	IF	CITATIONS
181	Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes. Journal of Diabetes and Its Complications, 2021, 35, 107978.	2.3	5
182	Diagnosis and treatment of hyperhomocysteinemia. Current Atherosclerosis Reports, 2001, 3, 54-63.	4.8	4
183	Optimizing treatment goals for long-term health outcomes among patients with type 2 diabetes mellitus. BMJ Open Diabetes Research and Care, 2021, 9, e002396.	2.8	4
184	The Association Between Baseline Insulin Treatment and Cardiovascular Events: A Meta-Analysis. Journal of the Endocrine Society, 2021, 5, bvaa193.	0.2	4
185	KDIGO recommendations for the evaluation of glycemic control in advanced chronic kidney disease. Kidney International, 2022, 101, 420.	5.2	4
186	Projected Impact of the Medicare Part D Senior Savings Model on Diabetes-Related Health and Economic Outcomes Among Insulin Users Covered by Medicare. Diabetes Care, 2022, 45, 1814-1821.	8.6	4
187	Evaluating the Cardiovascular Effects of the Thiazolidinediones and Their Place in the Management of Type 2 Diabetes in Relation to the Metabolic Syndrome. Metabolic Syndrome and Related Disorders, 2005, 3, 147-173.	1.3	3
188	Metabolic Syndrome and Heart Failure. Heart Failure Clinics, 2006, 2, 1-11.	2.1	3
189	Introduction. American Journal of Medicine, 2009, 122, S1-S2.	1.5	3
190	Adding subcutaneous liraglutide to metformin reduces HbA1c more than adding oral sitagliptin in patients whose type 2 diabetes is poorly controlled with metformin alone. Evidence-Based Medicine, 2010, 15, 115-116.	0.6	3
191	The enigma of glucose and cardiovascular disease. Heart, 2010, 96, 649-651.	2.9	3
192	Dethroning the king?: The future of metformin as first line therapy in type 2 diabetes. Journal of Diabetes and Its Complications, 2019, 33, 462-464.	2.3	3
193	Birth weight modifies the relation between adulthood levels of insulin-like growth factor-1 and type 2 diabetes: a prospective cohort study. BMJ Open Diabetes Research and Care, 2021, 9, e001885.	2.8	3
194	Socioeconomic Factors Play a More Important Role than Clinical Needs in the Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in People With Type 2 Diabetes. Diabetes Care, 2022, 45, e32-e33.	8.6	3
195	Pioglitazone. Drugs, 2000, 60, 344-345.	10.9	2
196	Effects of thiazolidinediones on cardiovascular risk factors. Comprehensive Therapy, 2002, 28, 200-206.	0.2	2
197	What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?. Current Diabetes Reports, 2016, 16, 94.	4.2	2
198	Inpatient management and post-discharge outcomes of hyperkalemia. Hospital Practice (1995), 2021, 49, 273-279.	1.0	2

#	Article	IF	CITATIONS
199	Efficacy of iGlarLixi on 5-year risk of diabetes-related complications: A simulation study. Journal of Diabetes and Its Complications, 2022, 36, 108132.	2.3	2
200	Menopausal hormone therapy and risk of cardiovascular events in women with prediabetes or type 2 diabetes: A pooled analysis of 2917 postmenopausal women. Atherosclerosis, 2022, 344, 13-19.	0.8	2
201	Changes in body size phenotypes from childhood to adulthood and the associated cardiometabolic outcomes. Diabetes Research and Clinical Practice, 2022, 187, 109884.	2.8	2
202	The Joint Secular Trends of Sleep Quality and Diabetes Among US Adults, 2005-2018. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 3152-3161.	3.6	2
203	Of Hopes and DREAMS: The Quest to Prevent Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4762-4763.	3.6	1
204	Colesevelam hydrochloride: a bile acid sequestrant for glycemic control and treatment of dyslipidemia in Type 2 diabetes mellitus. Therapy: Open Access in Clinical Medicine, 2009, 6, 475-487.	0.2	1
205	Effects of Linagliptin on Pancreatic α Cells of Type 1 Diabetic Mice. Journal of the Endocrine Society, 2017, 1, 1224-1234.	0.2	1
206	Response by Mann et al to Letter Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial― Circulation, 2019, 139, e1017-e1018.	1.6	1
207	Comment on Segar et al. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. Diabetes Care 2019;42:2298–2306. Diabetes Care, 2020, 43, e25-e25.	8.6	1
208	Rationale for the Use of Combination Injectable Therapy in Patients With Type 2 Diabetes Who Have High A1C (≥9%) and/or Long Duration (>8 Years): Executive Summary. Clinical Diabetes, 2021, 39, 141-145.	2.2	1
209	174-LB: Impact of Quality Improvement (QI) Program on 5-Year Risk of Diabetes-Related Complications. Diabetes, 2019, 68, .	0.6	1
210	Effects of low-dose candesartan on the rate of re-endothelialisation following vascular wound healing. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2001, 2, S81-S83.	1.7	0
211	Pharmacological Treatment of the Insulin Resistance Syndrome in People Without Diabetes. Metabolic Syndrome and Related Disorders, 2005, 3, 332-338.	1.3	0
212	DPP-4 inhibitors as a new target of action for Type 2 diabetes mellitus: a focus on vildagliptin. Expert Review of Endocrinology and Metabolism, 2007, 2, 567-572.	2.4	0
213	Introduction. European Journal of Internal Medicine, 2009, 20, S301-S302.	2.2	0
214	Introduction. American Journal of Medicine, 2011, 124, S1-S2.	1.5	0
215	How to get your paper published paper: An editor's perspective. Journal of Diabetes and Its Complications, 2014, 28, 1-3.	2.3	0
216	Post-ACA Racial Disparity of Eye Examinations Among the U.S. Noninstitutionalized Population With Diabetes: 2014–2015. Diabetes Care, 2019, 42, e70-e72.	8.6	0

#	Article	IF	CITATIONS
217	The diminishing cost-effectiveness of the newer glucose-lowering drug classes in the United States: 2010–2018. Current Medical Research and Opinion, 2021, 37, 1-6.	1.9	0
218	Stroke prevention in diabetes with glucagon-like peptide-1 receptor agonists: A game-changer?. Journal of Diabetes and Its Complications, 2021, 35, 108075.	2.3	0
219	Pharmacological Treatment of the Insulin Resistance Syndrome in People Without Diabetes. Metabolic Syndrome and Related Disorders, 2005, 3, 260-266.	1.3	0
220	Metabolic Syndrome and Type 2 Diabetes Mellitus. , 2006, , 41-78.		0
221	Insulin Resistance Syndrome and Its Vascular Complications. , 2007, , 375-393.		0
222	Intensive Treatment and Complications of Diabetes. , 2008, , 51-68.		0
223	Complications of diabetes. , 2009, , 41-57.		0
224	MON-160 Effect Of The Combination Conjugated Estrogens And Bazedoxifene On Glucose Homeostasis In Obese Postmenopausal Women: A Placebo-controlled Randomized Pilot Trial. Journal of the Endocrine Society, 2019, 3, .	0.2	0
225	Insulin Sensitizers and Cardiovascular Disease. , 2009, , 81-95.		0
226	Therapieintensivierung bei mit basalunterstützter oraler Therapie (BOT) unkontrolliertem Typ-2-Diabetes: Subanalyse der SoliMix-Studie bei Teilnehmern in Europa. Diabetologie Und Stoffwechsel, 2022, , .	0.0	0
227	Therapieintensivierung bei mit basalunterstützter oraler Therapie (BOT) unkontrolliertem Typ-2-Diabetes: Nähtliche Hypoglykänien in der SoliMix-Studie. Diabetologie Und Stoffwechsel, 2022, ,	0.0	0
228	Therapieintensivierung bei Typ-2-Diabetespatienten mit basalunterstützter oraler Therapie (BOT): Hypoglyk¤nien als Funktion des HbA1c in der SoliMix-Studie. Diabetologie Und Stoffwechsel, 2022, , .	0.0	0